Advertisement
Advertisement
VERA
Vera Therapeutics, Inc. Class A Common Stock
30.71
USDSponsored
+0.18
+0.59%
Oct 30, 14:22 UTC -4
Open
Vera Therapeutics, Inc. Class A Common Stock (VERA) Earnings
VERA Earnings Reports
Positive Surprise Ratio
VERA beat 7 of 22 last estimates.
32%
Next Report
Next Week
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$4.04M
/-$1.64
Implied change from Q2 26 (Revenue/ EPS)
--
/+7.89%
Implied change from Q3 25 (Revenue/ EPS)
--
/+30.16%
Vera Therapeutics, Inc. Class A Common Stock earnings per share and revenue
On Aug 10, 2026, VERA reported earnings of -1.52 USD per share (EPS) for Q2 26, beating the estimate of -1.60 USD, resulting in a 5.47% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.08% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -1.64 USD, with revenue projected to reach 4.04 million USD, implying an increase of 7.89% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
PTC Therapeutics, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.34
Actual
$0.61
Surprise
+75.59%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
FAQ
What were Vera Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Vera Therapeutics, Inc. Class A Common Stock reported EPS of -$1.52, beating estimates by 5.47%, and revenue of $0.00, 0% as expectations.
How did the market react to Vera Therapeutics, Inc. Class A Common Stock's Q2 2026 earnings?
The stock price moved down -4.08%, changed from $31.58 before the earnings release to $30.29 the day after.
When is Vera Therapeutics, Inc. Class A Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Vera Therapeutics, Inc. Class A Common Stock's next earnings report?
Based on --
analysts, Vera Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$1.64 and revenue of $4.04M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.